Literature DB >> 25359589

Neurofunctional effects of quetiapine in patients with bipolar mania.

Andrew K Davis1, Melissa P DelBello1, James Eliassen1,2, Jeffrey Welge1, Thomas J Blom1, David E Fleck1,2, Wade A Weber1, Kelly B Jarvis1, Emily Rummelhoff1, Stephen M Strakowski1,2, Caleb M Adler1,2.   

Abstract

OBJECTIVES: Several lines of evidence suggest that abnormalities within portions of the extended limbic network involved in affective regulation and expression contribute to the neuropathophysiology of bipolar disorder. In particular, portions of the prefrontal cortex have been implicated in the appearance of manic symptomatology. The effect of atypical antipsychotics on activation of these regions, however, remains poorly understood.
METHODS: Twenty-two patients diagnosed with bipolar mania and 26 healthy subjects participated in a baseline functional magnetic resonance imaging scan during which they performed a continuous performance task with neutral and emotional distractors. Nineteen patients with bipolar disorder were treated for eight weeks with quetiapine monotherapy and then rescanned. Regional activity in response to emotional stimuli was compared between healthy and manic subjects at baseline; and in the subjects with bipolar disorder between baseline and eight-week scans.
RESULTS: At baseline, functional activity did not differ between subjects with bipolar disorder and healthy subjects in any region examined. After eight weeks of treatment, subjects with bipolar disorder showed a significant decrease in ratings on the Young Mania Rating Scale (YMRS) (p < 0.001), and increased activation in the right orbitofrontal cortex (OFC) (p = 0.002); there was a significant association between increased right OFC activity and YMRS improvement (p = 0.003).
CONCLUSIONS: These findings are consistent with suggestions that mania involves a loss of emotional modulatory activity in the prefrontal cortex--restoration of the relatively greater elevation in prefrontal activity widely observed in euthymic patients is associated with clinical improvement. It is not clear, however, whether changes are related to quetiapine treatment or represent a non-specific marker of affective change.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  bipolar disorder; fMRI; functional magnetic resonance imaging; mania; prefrontal cortex; quetiapine

Mesh:

Substances:

Year:  2014        PMID: 25359589     DOI: 10.1111/bdi.12274

Source DB:  PubMed          Journal:  Bipolar Disord        ISSN: 1398-5647            Impact factor:   6.744


  4 in total

1.  Neurofunctional Correlates of Response to Quetiapine in Adolescents with Bipolar Depression.

Authors:  Kiki Chang; Melissa DelBello; Amy Garrett; Ryan Kelley; Meghan Howe; Cal Adler; Jeffrey Welge; Stephen M Strakowski; Manpreet Singh
Journal:  J Child Adolesc Psychopharmacol       Date:  2018-05-30       Impact factor: 2.576

2.  fMRI brain activation changes following treatment of a first bipolar manic episode.

Authors:  Stephen M Strakowski; David E Fleck; Jeffrey Welge; James C Eliassen; Matthew Norris; Michelle Durling; Richard A Komoroski; Wen-Jang Chu; Wade Weber; Jonathan A Dudley; Thomas J Blom; Amanda Stover; Christina Klein; Jeffrey R Strawn; Melissa P DelBello; Jing-Huei Lee; Caleb M Adler
Journal:  Bipolar Disord       Date:  2016-09-19       Impact factor: 6.744

3.  Effects of short-term quetiapine and lithium therapy for acute manic or mixed episodes on the limbic system and emotion regulation circuitry in youth with bipolar disorder.

Authors:  Du Lei; Wenbin Li; Kun Qin; Yuan Ai; Maxwell J Tallman; L Rodrigo Patino; Jeffrey A Welge; Thomas J Blom; Christina C Klein; David E Fleck; Qiyong Gong; Caleb M Adler; Jeffrey R Strawn; John A Sweeney; Melissa P DelBello
Journal:  Neuropsychopharmacology       Date:  2022-10-13       Impact factor: 8.294

4.  Changes in the structural brain connectome over the course of a nonrandomized clinical trial for acute mania.

Authors:  Du Lei; Wenbin Li; Maxwell J Tallman; Stephen M Strakowski; Melissa P DelBello; L Rodrigo Patino; David E Fleck; Su Lui; Qiyong Gong; John A Sweeney; Jeffrey R Strawn; Fabiano G Nery; Jeffrey A Welge; Emily Rummelhoff; Caleb M Adler
Journal:  Neuropsychopharmacology       Date:  2022-05-18       Impact factor: 8.294

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.